AR075912A1 -
USE OF CLOPIDOGREL WITH ACETILSALICILIC ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF HEADPHONES FIBRILATION
- Google Patents
USE OF CLOPIDOGREL WITH ACETILSALICILIC ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF HEADPHONES FIBRILATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi AventisfiledCriticalSanofi Aventis
Priority to ARP100100910priorityCriticalpatent/AR075912A1/en
Publication of AR075912A1publicationCriticalpatent/AR075912A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Reivindicacion 1: Uso de clopidogrel y ácido acetilsalicílico para la preparacion de un medicamento con el que se pretende reducir al menos un evento vascular mayor en pacientes que tienen una historia de fibrilacion auricular. Reivindicacion 2: Uso segun la reivindicacion 1, para la preparacion de un medicamento en la prevencion de ictus. Reivindicacion 3: Uso segun la reivindicacion 1 o 2, para la preparacion de un medicamento en la prevencion de infarto de miocardio.Claim 1: Use of clopidogrel and acetylsalicylic acid for the preparation of a medicament with which it is intended to reduce at least one major vascular event in patients who have a history of atrial fibrillation. Claim 2: Use according to claim 1, for the preparation of a medicament in the prevention of stroke. Claim 3: Use according to claim 1 or 2, for the preparation of a medicament in the prevention of myocardial infarction.
ARP1001009102010-03-222010-03-22
USE OF CLOPIDOGREL WITH ACETILSALICILIC ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF HEADPHONES FIBRILATION
AR075912A1
(en)
Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
Use of a pharmaceutical composition comprising: a) a monohydrated compound consisting of two anions and an ob) valsartan cation and an ethyl acid ester, for the treatment of hypertension and / or the prevention or treatment of heart failure in a mammal that receives anti-coagulant therapy.
USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY IN PA-HUNDREDS WHO HAVE A FIRST RECURRENCE OF HEADPHONES OR ALE-TEO HEADPHONES